Biogen Inc.
BIIB
$129.44
$3.853.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.43B | 2.45B | 2.47B | 2.46B | 2.29B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.43B | 2.45B | 2.47B | 2.46B | 2.29B |
| Cost of Revenue | 577.90M | 583.50M | 638.70M | 501.90M | 498.10M |
| Gross Profit | 1.85B | 1.87B | 1.83B | 1.96B | 1.79B |
| SG&A Expenses | 574.60M | 678.70M | 576.90M | 550.30M | 578.30M |
| Depreciation & Amortization | 111.80M | 91.00M | 130.30M | 86.90M | 78.30M |
| Other Operating Expenses | 58.10M | 57.10M | 69.30M | 62.40M | 65.60M |
| Total Operating Expenses | 1.75B | 1.93B | 1.95B | 1.66B | 1.66B |
| Operating Income | 681.90M | 527.90M | 511.40M | 801.00M | 632.40M |
| Income Before Tax | 311.20M | 291.50M | 451.00M | 698.70M | 464.80M |
| Income Tax Expenses | 70.70M | 24.80M | 62.50M | 115.10M | 71.40M |
| Earnings from Continuing Operations | 240.50M | 266.70M | 388.50M | 583.60M | 393.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 240.50M | 266.70M | 388.50M | 583.60M | 393.40M |
| EBIT | 681.90M | 527.90M | 511.40M | 801.00M | 632.40M |
| EBITDA | 865.10M | 711.90M | 694.20M | 959.90M | 779.90M |
| EPS Basic | 1.65 | 1.83 | 2.67 | 4.01 | 2.71 |
| Normalized Basic EPS | 2.78 | 2.35 | 1.96 | 3.20 | 2.45 |
| EPS Diluted | 1.64 | 1.82 | 2.66 | 4.00 | 2.70 |
| Normalized Diluted EPS | 2.77 | 2.34 | 1.96 | 3.20 | 2.44 |
| Average Basic Shares Outstanding | 146.10M | 145.70M | 145.70M | 145.60M | 145.20M |
| Average Diluted Shares Outstanding | 146.60M | 146.10M | 146.10M | 145.90M | 145.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |